In angioplasty procedures, a balloon is fed through a catheter and used to prop open an artery that has become narrowed or blocked. In cases where stenting is appropriate, a stent mounted on a balloon is inserted and inflation of the balloon expands the stent against the blocked artery wall to hold the vessel open. The balloon is then deflated and the catheter is withdrawn. Stent treatment of arteries holds them open and improves blood flow to the heart. In cases where post-dilatation is needed, a high-pressure balloon is inflated inside a stent to help better place the stent against the vessel wall.
Covidien, a leading global provider of healthcare products, today announced that it has completed the previously announced acquisition of ev3 Inc. for an aggregate consideration of approximately $2.6 billion, net of cash and short-term investments acquired.
AngioDynamics announced today the global expansion of its Smart Port CT family of power-injectable ports, featuring its patented Vortex® port technology - to include low-profile and mini models for repeated treatments such as chemotherapy and for use with computed tomography (CT).
The Society of Interventional Radiology, with the support of 41 international societies representing 10,000 interventional radiology doctors, has issued the first global statement defining interventional radiology-one designed to benefit medical treatment for individuals. The statement addresses the evolution, impact and future direction of this minimally invasive specialty, emphasizing the worldwide availability of this specialized medical care.
A large U.S. multicenter study shows that older men with higher testosterone levels are more likely to have a heart attack or other cardiovascular disease in the future. The results were presented at The Endocrine Society's 92nd Annual Meeting in San Diego.
Buffalo medical researchers led by a team from the University at Buffalo Department of Neurosurgery, will embark on a landmark prospective randomized double-blinded study to test the safety and efficacy of interventional endovascular therapy -- dubbed "liberation treatment" -- on the symptoms and progression of Multiple Sclerosis.
The diabetes drug rosiglitazone has been under intense scrutiny since a 2007 study in the New England Journal of Medicine looked at more than 40 clinical trials and linked the drug's use with increased risk of heart attack and death from heart disease.
According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, despite the rising popularity of drug-eluting stents (DES) across Latin America, bare-metal stents (BMS) will continue to represent a significant portion of the overall coronary stent market through 2014. This trend is especially evident in Brazil, where the public healthcare system does not provide any reimbursement for DES procedures.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Women who experience early menopause appear to have more than twice the risk of having a heart attack, stroke or other cardiovascular disease event later in life than do women who do not go through early menopause, a new study indicates. The results will be presented Saturday at The Endocrine Society's 92nd Annual Meeting in San Diego.
Boston Scientific Corporation today announced that 22 new balloon sizes have been added to the PolarCath® Peripheral Dilatation System, including balloon lengths of 120 and 150 mm. The PolarCath System is used to restore blood flow in patients with critical limb ischemia (severe blockages in the arteries below the knee) and blockages in the femoral and popliteal (behind the knee) arteries. Both conditions result from peripheral artery disease.
ev3 Inc., a global endovascular device company, today announced that the U.S. Food and Drug Administration (FDA) formally accepted for filing the company's Pre-Market Approval (PMA) application for the Pipeline Embolization Device for treatment of large, giant and wide-necked cerebral aneurysms. The FDA's action means that the PMA application was sufficiently complete and ready for substantive review. The filing date for regulatory purposes is May 18, 2010, the date the FDA received ev3's PMA submission.
InfraReDx, Inc., an innovative medical device company focused on developing novel diagnostic imaging technologies to accurately identify and characterize diseased tissues, today announced that its LipiScan Coronary Imaging System will be featured at the 13th Annual Live Symposium of Complex Coronary & Vascular Cases being held at The Mount Sinai Medical Center of New York, from June 16-19, 2010.
Researchers from the Frances Payne Bolton School of Nursing at Case Western Reserve University found that one year after 248 individuals completed a 12-week cardiac rehabilitation program following a heart attack, bypass surgery or angioplasty, only 37% exercised three times a week to keep their hearts healthy.
Cook Medical has submitted its Pre-Market Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the company's unique polymer-free Zilver® PTX® Drug-Eluting Peripheral Stent. Intended for use in patients with peripheral arterial disease (PAD) in the superficial femoral artery (SFA), Zilver PTX is a self-expanding, highly durable nitinol stent that uses a proprietary, polymer-free technology to deliver a locally therapeutic dose of paclitaxel, an antiproliferative drug, to the target lesion.
Duplex guided dialysis access angioplasty can be performed safely and effectively in the office setting according to a new study presented today at the 64th Vascular Annual Meeting presented by the Society for Vascular Surgery®. According to researchers, ultrasound offers the advantage of treating the patient without ionizing radiation and sedation or iodinated contrast.
The Spectranetics Corporation today announced its clinical trial plans related to the treatment of in-stent restenosis (ISR) in arteries above the knee, which remains a major unsolved medical problem. There is no device currently cleared or approved by the FDA to treat ISR.
Biomet, a global leader in the manufacture of orthopedic and biotechnology products, announced today that its subsidiary, Biomet Biologics, has enrolled the first subject into its multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial for critical limb ischemia (CLI).
In a study that included data from more than 1.5 million patients, use of vascular closure devices and the anticoagulant bivalirudin were associated with significantly lower bleeding rates for patients following a percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), according to a study in the June 2 issue of JAMA. The researchers also found that patients who may benefit most from these treatments, those at greatest risk of bleeding, were least likely to receive them.
An examination of the treatment received by patients with myocardial infarction (heart attack) at 80 hospitals in Quebec indicates that those who received either primary percutaneous coronary intervention (PPCI; such as angioplasty) or fibrinolysis (administration of medication to dissolve blood clots) beyond the times recommended in international guidelines had a significantly increased risk of death within 30 days, along with an increased risk of the combined outcome of death or readmission for heart attack or heart failure at one year, according to a study in the June 2 issue of JAMA.
NovoStent Corporation, a privately held medical device company, today announced the 6-month follow-up results of the company's European clinical trial evaluating the use of its SAMBA Stent and Delivery System in the treatment of superficial femoral and popliteal artery disease. The SAMBA Stent was designed to treat the highly varied presentation of atherosclerotic disease in the superficial femoral (SFA) and popliteal arteries by providing a unique combination of increased vessel coverage, strength and flexibility.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.